Dr. Stanislaw R. Burzynski Featured Speaker at Cleveland Clinic,Neuro-Oncology S

[Guest guest]

http://ragingbull.lycos.com/mboard/boards.cgi?board=BZYR & read=535

 

 

 

Press Release Source: Burzynski Research Institute

 

 

 

 

Houston's Dr. Stanislaw R. Burzynski Featured Speaker at Cleveland

Clinic

Neuro-Oncology Symposium

Monday January 31, 12:53 pm ET

 

ORLANDO, Fla., Jan. 31, 2005 (PRIMEZONE) -- Stanislaw R. Burzynski,

M.D.,

Ph.D., founder and CEO of the Burzynski Clinic and President of the

Burzynski Research Institute, Inc. (OTC BB:BZYR.OB - News) in

Houston, was

a featured speaker at Neuro-Oncology 2005, the Cleveland Clinic's

Annual

Brain Tumor Symposium. Dr. Burzynski spoke about his pioneering

research

in targeted genetic cancer treatment and the development of

Antineoplastons,

which he and his research team discovered in the 1970s. Since that

time,

researchers at the Burzynski Clinic have developed these naturally

occurring

anti-tumor agents synthetically -- to the point that it is now

possible to

manufacture them commercially.

 

Dr. Burzynski's presentation concentrated on mechanisms of anti-tumor

activity of synthetic antineoplastons, as well as statistical results

of on-going

clinical trials in brain stem glioma and glioblastoma multiforme. His

conclusions, based on Phase II clinical trials of antineoplastons,

indicated

good tolerance, significant response rates and long-term survival in

patients

with difficult to treat primary brain tumors.

 

Following the presentation, Dr. Burzynski left for Paris, where he

will address

the 16th International Congress on Anti-Cancer Treatment (ICACT) --

February 1-4, 2005. His presentation, entitled ``Targeted Therapy

with

Antineoplastons A10 and AS2-1 (ANP) of High Grade, Recurrent and

Progressive Brain Stem Glioma (HBSG),'' will support the hypothesis

that

antineoplastons will provide longer survival and a greater number of

objective

responses in HBSG patients than those receiving standard therapy, as

reported by current clinical literature.

 

Forward-looking statements in this release are made pursuant to the

safe

harbor provisions of the federal securities laws. BRI cautions

investors not to

place undue reliance on the forward-looking statements contained in

this

press release. Information contained in forward-looking statements is

based

on current expectations and is subject to change, and future events

may differ

materially from those discussed herein due to a number of factors,

including,

but not limited to, risks and uncertainties related to BRI's ability

to obtain

regulatory approval for Antineoplastons A10 and AS2-1. BRI does not

undertake to update any such forward-looking statements or to

publicly

announce developments or events relating to the matters described

herein.

 

The Burzynski Research Institute logo can be found at: http://

www.primezone.com/newsroom/prs/?pkgid=1291

 

Comments: Featured speaker at two prestigious oncology symposiums.

First,

at Cleveland Clinic and then Paris, France the next day!!!! Wow!!

 

 

(Voluntary Disclosure: Position- Long)